. VHL loss activates the HIF-2 transcription factor, and constitutive HIF-2 activity restores tumorigenesis in VHL-reconstituted ccRCC cells 5 . HIF-2 has been implicated in angiogenesis and multiple other processes 6-9 , but angiogenesis is the main target of drugs such as the tyrosine kinase inhibitor sunitinib 10 . HIF-2 has been regarded as undruggable 11 . Here we use a tumourgraft/patient-derived xenograft platform 12,13 to evaluate PT2399, a selective HIF-2 antagonist that was identified using a structure-based design approach. PT2399 dissociated HIF-2 (an obligatory heterodimer of HIF-2α-HIF-1β) 14 in human ccRCC cells and suppressed tumorigenesis in 56% (10 out of 18) of such lines. PT2399 had greater activity than sunitinib, was active in sunitinib-progressing tumours, and was better tolerated. Unexpectedly, some VHL-mutant ccRCCs were resistant to PT2399. Resistance occurred despite HIF-2 dissociation in tumours and evidence of Hif-2 inhibition in the mouse, as determined by suppression of circulating erythropoietin, a HIF-2 target 15 and possible pharmacodynamic marker. We identified a HIF-2-dependent gene signature in sensitive tumours. Gene expression was largely unaffected by PT2399 in resistant tumours, illustrating the specificity of the drug. Sensitive tumours exhibited a distinguishing gene expression signature and generally higher levels of HIF-2α. Prolonged PT2399 treatment led to resistance. We identified binding site and second site suppressor mutations in HIF-2α and HIF-1β, respectively. Both mutations preserved HIF-2 dimers despite treatment with PT2399. Finally, an extensively pretreated patient whose tumour had given rise to a sensitive tumourgraft showed disease control for more than 11 months when treated with a close analogue of PT2399, PT2385. We validate HIF-2 as a target in ccRCC, show that some ccRCCs are HIF-2 independent, and set the stage for biomarker-driven clinical trials.
The discovery of a 280 Å 3 cavity within the PAS-B domain of HIF-2α 16, 17 and subsequent identification of compounds that bound this cavity and dissociated HIF-2α from HIF-1β 18 led to an iterative structure-based program that identified selective, potent HIF-2α antagonists such as PT2399 (described in ref. 19 ) and PT2385 (ref. 20) .
To evaluate PT2399 in renal cancer, we tested a panel of 22 independently generated tumourgrafts 12,13 (Extended Data Table 1 ). To assess the drug's tolerability, we evaluated its effects on weight and blood counts in mice bearing these tumourgrafts. PT2399 did not induce weight loss, whereas sunitinib, at doses matching human exposures 13 , did (Fig. 1a) . However, PT2399 caused modest anaemia and leukopaenia ( Fig. 1b and Extended Data Fig. 1a) .
We hypothesized that the reduction in haemoglobin (2.0 g dl −1 ; P = 0.0001) was due to a decrease in erythropoietin (EPO), which is regulated by HIF-2 15 . Consistent with this hypothesis, the number of red blood cell precursors was decreased by 35% (P < 0.0001; Fig. 1b ) and the level of EPO, which may serve as a pharmacodynamic marker, was suppressed by 75% (P < 0.0001; Fig. 1b) .
PT2399 decreased tumour growth by 60% across all tumourgrafts evaluated (P < 0.0001; Fig. 1c ). According to their responsiveness, tumourgrafts were classified into sensitive (tumour growth inhibition at last measurement > 80%), intermediate (40-80%), and resistant (< 40%; Extended Data Table 1 ). Forty-five percent of tumourgrafts were sensitive (10/22), 23% intermediate, and 32% resistant ( Fig. 1d and Extended Data Fig. 1b, c) . Sensitive tumours included tumours with aggressive sarcomatoid and rhabdoid features (Extended Data  Table 1 ). Among ccRCC tumourgrafts, 56% (10/18) were sensitive. Unexpectedly, four ccRCCs were resistant to PT2399, including three with VHL mutations (Extended Data Table 1). PT2399 was more active than sunitinib (P = 0.0126) ( Fig. 1c and Extended Data Fig. 1b ) and inhibited tumour growth in several sunitinib-resistant tumours (Fig. 1d) . There was no bias in treatment allocation, as treatment groups were balanced (pre-trial: tumour size, P = 0.11; tumour growth rate, P = 0.22; and mouse weight, P = 0.34). PT2399 reduced tumour cell density and increased fibrosis (Extended Data Fig. 1c-e) . Ki67 immunohistochemistry (IHC) showed that PT2399 inhibited tumour cell proliferation by 3.5-fold (mean value change of − 19.5 ± 2.4; P < 0.0001; Extended Data Fig. 1e, f) . Inhibition of cell proliferation was also observed in live mice using 3′ -[
18 F] fluoro-3′ -deoxythymidine positron emission tomography/computerized tomography (PET/CT) scanning (Extended Data Fig. 1g, h ). In addition, PT2399 collapsed the tumour vasculature, decreasing vascular area threefold (mean value change of −29.1 ± 6.1; P = 0.0011) (Extended Data Fig. 1e, f) . To determine whether changes in vascular area were due to inhibition of tumour VEGF, we exploited the species difference between graft (human) and host (mouse). PT2399 suppressed circulating human VEGF by 93%, but mouse VEGF was unaffected (Extended Data Fig. 1i ). Thus, tumour VEGF production, but not extratumoral VEGF, is HIF-2-dependent and inhibited by PT2399. This tumour selectivity represents a marked improvement over current angiogenesis inhibitors. PT2399 also inhibited VEGF production in tumours progressing on sunitinib (Extended Data Fig. 2) .
We evaluated the effects of PT2399 on HIF-2 in tumours. Immunoprecipitation of the HIF-1β subunit, which is shared by both HIF-2α and HIF-1α , showed that PT2399 specifically disassembled HIF-2 but not HIF-1 complexes (Fig. 2a) . Similar results were observed using a proximity ligation assay (Fig. 2b) . Correspondingly, PT2399 reduced the expression of HIF-2 target genes (VEGFA, SERPINE1 (encoding PAI-1), IGFBP3, CCND1 (encoding cyclin D1), TGFA, and SLC2A1 (encoding GLUT1); all comparisons P < 0.05; Fig. 2c ), but not HIF-1 targets (CA9, PGK1, and LDHA).
Notably, PT2399 did not affect the majority of HIF-2 target genes in resistant tumours (Fig. 2c) . A modest decrease in VEGFA mRNA did not translate into lower circulating vascular endothelial growth factor (VEGF; Fig. 2d ). However, as determined by a reduction in EPO (P = 0.0002; Fig. 2d ), Hif-2 was inhibited by PT2399 in mice with resistant tumours. Furthermore, immunoprecipitation experiments showed that HIF-2 complexes were dissociated in resistant tumours (Fig. 2a) . Thus, somewhat unexpectedly, PT2399 disassembled HIF-2 in resistant tumours, but HIF-2 target genes were largely unaffected.
To better characterize the effects of PT2399, we performed RNA sequencing (RNA-seq) on 46 tumours (Extended Data Tables 1, 2) . In sensitive tumours, we identified 492 RNAs that were deregulated by PT2399 (FDR < 0.05; Fig. 2e and Extended Data Table 3 ). By contrast, the same analysis in resistant tumours found no genes that were deregulated by PT2399 (Fig. 2e, f) . Similar results were obtained by an independent, blinded analysis (H.G. and C.R.). The selective changes induced by PT2399 in sensitive tumours suggest that PT2399 sensitivity is linked to its ability to alter gene expression. Furthermore, the lack of gene expression changes in resistant tumours suggest that PT2399 a, Mean change in mouse body weights after treatment with vehicle (n = 89), PT2399 (100 mg kg −1 ) by oral gavage every 12 h (n = 96) or sunitinib (10 mg kg −1 ) by oral gavage every 12 h (n = 82). b, Haemoglobin levels, reticulocyte counts, and erythropoietin (EPO) levels in mice treated as indicated. Haemoglobin and reticulocytes: vehicle n = 52 mice, PT2399 n = 58, sunitinib n = 53; EPO: vehicle n = 63, PT2399 n = 74, sunitinib n = 61. c, Mean per cent change in tumour volume in mice treated with vehicle (n = 89), PT2399 (n = 96), or sunitinib (n = 82). d, Growth curves of each tumourgraft line grouped according to PT2399 responsiveness into sensitive (growth inhibition (GI) at end of trial > 80%), intermediate (GI = 40-80%), or resistant (GI < 40%). Treatment starts on day 0 and values and error bars represent mean tumour volume ± s.e.m. To minimize bias (despite overestimation) volumes were calculated as length × width × height. Each tumourgraft line had n ≈ 3-5 tumours per treatment group (vehicle n = 89 mice, PT2399 n = 96, sunitinib n = 82). a-c, Tests completed using a mixed model with compound symmetrical covariance structure for mice in the same tumourgraft line using vehicle as the reference group. Reticulocyte values were log-transformed for analysis; EPO levels were Box-Cox transformed; raw values are depicted in all figures. All bar charts depict the mean tumour volume with the error bar representing s.e.m., while all boxplots have median centre values. **P < 0.01; ***P < 0.001; ****P < 0.0001. qRT-PCR levels were log-transformed for analysis; EPO and hVEGF levels were Box-Cox transformed; RNA-seq levels were log 2 -transformed; raw values depicted in all graphs. All bar charts depict the mean with the error bar representing s.e.m., while all boxplots have median centre values. * P < 0.05; * * P < 0.01; * * * P < 0.001; * * * * P < 0.0001. See Supplementary  Fig. 1 for gel source images. V4232  V4237  V4226  P4244  P4249  P4250  V4232  V4237  V4226  P4244  P4249  P4250   XP373   Input  IP HIF-1β   Tubulin   Vehicle  PT2399  PT2399  Vehicle   HIF-2α   HIF-1α   HIF-1β   V4574  V4582  V4579  P4572  P4575  P4578  V4574  V4582  V4579  P4572  P4575 Relative mRNA expression
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In t e r m e d ia t e R e s is t a n t S e n s it iv e In t e r m e d ia t e R e s is t a n t Letter reSeArCH is highly specific. Consistent with PT2399 specificity, PT2399 had less effect on overall gene expression than did subtle differences among patients' tumours (Extended Data Fig. 3a ).
Extensive studies have investigated HIF-2 target genes in ccRCC [21] [22] [23] . However, by leveraging (i) PT2399 specificity; (ii) RCC tumourgrafts, with minimal human stroma 24 ; and (iii) an RNA-seq algorithm excluding contaminating mouse (stromal) transcripts, we were able to define the HIF-2 program particularly accurately. Among the 492 RNAs that were deregulated in PT2399-sensitive tumours, 439 were protein coding, and 271 were downregulated; these included previously identified canonical HIF-2 targets (IGFBP3, SERPINE1, VEGFA, CCND1) as well as other genes such as LOX, CXCR4, IL6 and DDIT4 (also known as REDD1) (Extended Data Fig. 3b ). Pathway and gene set enrichment analyses showed downregulation of cell cycle, DNA replication, cell cycle checkpoint, and DNA repair processes (Extended Data Table 4 ). Regulation of DNA repair genes by HIF-2, as previously observed in cell lines 6 , may explain the resistance of ccRCC to radiotherapy. PT2399 increased the expression of 168 protein-coding genes, including fibrosisrelated genes (i.e. PDGFD), HIF1A (previously shown to be induced by HIF-2α knockdown 22 ), and FBP1, a gluconeogenic gene recently reported to suppress RCC progression 25 ( Fig. 2g and Extended Data Table 4 ).
We sought to identify a biomarker that could distinguish between PT2399-sensitive and resistant tumours. We found that HIF-2α protein was expressed in 83% of cells in sensitive tumours compared to 23% in resistant tumours (P < 0.0001; Fig. 3a, b and Extended Data Fig. 4a ). Although there were differences even within tumours, higher HIF-2α expression in sensitive tumours was observed by western blotting (Fig. 3c and Extended Data Fig. 4b ) and RT-PCR (Fig. 3d) . Lower, and at times undetectable, HIF-2α levels in resistant tumours may explain why PT2399 does not affect gene expression in this group.
Next, we compared RNA-seq data sets between sensitive and resistant vehicle-treated tumours. Using a rigorous Wilcox test, we identified 1,327 differentially expressed RNAs (Extended Data Table 3 ), including 94 (76 mRNAs) that were uniformly over-or underexpressed across every sensitive versus resistant tumour sample (Extended Data Fig. 4c and Extended Data Table 3 ). GLI1, a transcription factor of the sonic hedgehog family, and PTHLH (parathyroid hormone-like hormone), a neuroendocrine peptide that has been implicated in epithelialmesenchymal interactions and calcium ion transport, were uniformly overexpressed in sensitive tumours (Fig. 3e) . Notably, HIF1A expression was increased in the resistant group (Fig. 3e) . Increased expression of HIF-1α protein was also observed by immunohistochemistry in some, but not all, resistant tumours (Extended Data Fig. 4a ). EZH2 and MCAM were also uniformly overexpressed in resistant tumours (Fig. 3e) .
Overall, our data show that ccRCC can be classified into HIF-2-dependent and -independent tumours, and that these tumours differ in HIF-2α (and possibly HIF-1α ) levels and in their baseline gene expression. These tumour subtypes did not correlate with BRCA1 associated protein 1 (BAP1) and polybromo 1 (PBRM1) status 26 in this small series (Extended Data Table 1 ). Our results point to different mechanisms of tumorigenesis downstream of VHL that may underlie differences in tumour behaviour or responsiveness to therapy.
Given the differences in gene expression, we investigated whether sensitive and resistant tumours showed differing imaging characteristics. We obtained CT scan images from patient tumours giving rise to tumourgrafts before surgery. The sensitive group was characterized by tumours with peripheral hypervascularity and a central non-enhancing area (typical of high-grade ccRCC 27 ) and, if present, tumour infiltration was focal (Extended Data Fig. 5 ). The resistant group was more heterogeneous, but several tumours were relatively hypovascular and diffusely infiltrating (Extended Data Fig. 5 ).
We investigated whether sensitive tumours would acquire resistance. We exposed mice bearing tumours formed from a sensitive tumourgraft (XP164) to prolonged treatment with PT2399 or sunitinib. Sunitinib resistance developed within 60 days ( Fig. 4a ; compare to Fig. 1d ), but resistance to PT2399 took > 120 days (Fig. 4a) . PT2399 resistance was associated with increased tumour vascularity and higher tumour VEGF production (Fig. 4b) . We sequenced the HIF-2α gene (EPAS1) and identified a c.968G > A heterozygous mutation resulting in a G323E substitution in one tumour (Fig. 4c) . The mutation was absent in a vehicle-treated tumour and in the second resistant tumour XP26  XP144  XP164  XP374  XP454  XP534  XP165  XP373  XP453  XP469  XP258  XP462  XP506  XP530  XP169  XP296  XP490  XP164 HIF-2α Relative mRNA expression
Letter reSeArCH (despite originating from the same parental tumour). Structural analyses of HIF-2 17,28 showed that G323 is at the entrance to the cavity, where PT2399 binds (Fig. 4d) . Akin to engineered mutations 19, 29 , a glutamate side chain would prevent PT2399 access. Consistent with this notion, PT2399 failed to dissociate HIF-2 complexes in mutant tumours (Fig. 4e) .
We then sequenced HIF-1β from the second resistant tumour, and failed to identify a mutation. Nevertheless, HIF-2 complexes had reformed (Fig. 4e) . The tumour was passaged in mice, which were maintained on PT2399, and remained resistant. Immunoprecipitation experiments again showed dimeric HIF-2 complexes (Fig. 4f ) . Sequencing of passaged tumours revealed a heterozygous c.1338C > A mutation resulting in a F446L substitution in the HIF-1β PAS-B domain (Fig. 4c) . F446 is at the interface between HIF-1β and HIF-2α (Fig. 4d) . We postulate that F446L functions as a second-site suppressor mutation and that a more flexible side chain at the complex interface accommodates conformational changes induced by PT2399, allowing drug-bound HIF-2α to bind to HIF-1β . Experimentally, both HIF-1β (F446L) and HIF-2α (G323E), when expressed in cells, were sufficient to preserve the formation of HIF-2 dimers despite treatment with PT2399, and their effects appeared additive (Fig. 4g) . Overall, these results pave the way for second generation inhibitors or complementary approaches to leverage other potential drug-binding pockets that have been recently revealed 28 . Finally, a patient with metastatic ccRCC, whose tumour gave rise to a sensitive tumourgraft (XP165), enrolled in a phase 1 trial with PT2385 30 (NCT02293980). The patient, a 47-year-old male, had originally presented with omental and abdominal wall metastases following a radical nephrectomy of a stage III, high-grade ccRCC. After a failed attempt at surgical removal, he had received high-dose IL2, bevacizumab, and HIF-1β PAS-B domains differs, but F446 remains at the interface. e, HIF-1β immunoprecipitation from XP164 tumourgrafts before and after (red) development of resistance showing reformation of HIF-2α -HIF-1β complexes following the acquisition of resistance (V, vehicle; P, PT2399). f, HIF-1β immunoprecipitation from tumours of mice with HIF-2α or HIF-1β mutations (or wild-type controls) treated with PT2399 (n = 3 mice per group). g, FLAG immunoprecipitation from HEK293T cells transfected with plasmids encoding FLAG-tagged HIF-1β (FLAG-HIF-1β ; FLAG-HIF-1β -F446L) or HA-tagged HIF-2α (HA-HIF-2α ; HA-HIF-2α -G323E) treated with vehicle or PT2399. See Supplementary Fig. 1 for gel source images. Letter reSeArCH sorafenib, everolimus, sunitinib, pazopanib, and axitinib. Despite extensive pretreatment, he remained free of progression on PT2385 for more than 11 months (Extended Data Fig. 6 ). These data validate HIF-2 as a target for ccRCC, provide insight into HIF-2-mediated tumorigenesis, establish variable tumour dependency on HIF-2 identifying different ccRCC subtypes and associated biomarkers that may be incorporated in future clinical trials, showcase the specificity of PT2399, and anticipate mechanisms of resistance.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Nomenclature. Throughout the manuscript and figures, XP refers to the tumourgraft line; V refers to vehicle; S refers to sunitinib; and P refers to PT2399. Numbers following V, S, or P refer to the mouse identifier (ear tag) of that sample. Drug trials. Drug trials in tumourgraft-bearing mice were done as previously described 12, 13 . Briefly, ~ 64-mm 3 fragments of tissue from stably growing orthotopic tumourgrafts were implanted subcutaneously in 4-6-week-old female and male non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) mice. When tumour volumes reached ~ 300-600 mm 3 , mice were segregated into treatment groups (3-5 mice per group) based on (i) tumour volume, (ii) growth rate, and (iii) mouse weight. A sample size of five mice per treatment arm gave us 80% power to detect a significant tumour volume differential on the 28th day after treatment between the reference arm and a treatment arm using a two-sample t-test, assuming a true 600-mm 3 tumour volume difference with a standard deviation of 250 and attrition margin of ~ 20%. Since the mixed model analysis uses about eight repeated measures from each mouse, even with a few more covariates included in the model, the power will be similar or even higher. Vehicle (10% EtOH, 30% PEG400, 60% MCT (0.5% methyl cellulose, 0.5% Tween 80 (aq))) was administered by gavage every 12 h. Sunitinib (LC Laboratories) was administered by oral gavage every 12 h at 10 mg kg −1 in 0.5% carboxymethylcellulose (CMC) in D5W. PT2399 (Peloton Therapeutics, Inc.) was administered at 100 mg kg −1 by oral gavage in 10% EtOH, 30% PEG400, 60% MCT. Mouse weights were taken weekly and treatment doses were adjusted weekly. Tumours were generally measured twice a week using a digital caliper. While leading to an overestimation in tumour volumes, to minimize bias 12 , tumour volume was calculated by the formula: tumour volume = l × w × h, where l is the largest dimension of the tumour, w is the largest diameter perpendicular to l, and h is maximal height of the tumour. Trials typically lasted 4 weeks, but this varied depending upon tumour growth rates. Overall, > 14,000 measurements were obtained. Assuming a digital caliper measurement error rate up to 10%, 99.8% of measurements were within protocol limits. Consideration was given to tumour growth rates, curve separation and the foreseeable need for additional mice for repeat experiments. Mice were monitored during treatment and provided appropriate veterinary care. In accordance with UT Southwestern's Institutional Animal Care and Use Committee (IACUC) policies, animals were euthanized within timeframes specified by the veterinary staff once tumour diameters were greater than 2 cm. Mice were also euthanized if they exhibited signs of adverse clinical health. A total of n = 22 tumourgraft trials were completed with n = 89 vehicle-treated tumours FLT was prepared in saline containing 10% ethanol. Small animal PET/CT imaging studies were performed on a Siemens Inveon PET/CT Multimodality System. PET/CT scans were conducted on mice with both orthotopic and subcutaneous tumours. Orthotopic tumourgrafts were implanted using 2-3 pieces of 2 × 2 × 2-mm tissue underneath the left renal capsule of NOD/SCID mice. Once tumours became palpable, a baseline PET/CT scan was performed, and within 72 h, PT2399 treatment was started. PT2399 was continued for 8-10 days, after which a second PET/CT scan was performed to assess tumour response. After injection with 0.12 mCi of [ 18 ]FLT via the tail vein, and a 60-min wait period to allow for the radiotracer's distribution and uptake, mice were anaesthetized using 3% isoflurane, which was decreased to 2% during imaging. CT imaging was acquired at 80 kV and 500 μ A with a focal spot of 58 μ m. The PET imaging was acquired for 500 s directly following the acquisition of CT data. CT images were reconstructed with Cobra Reconstruction Software, and PET images were reconstructed using the OSEM3D algorithm. Reconstructed CT and PET images were fused and analysed using the manufacturer's software. For quantification, regions of interest were drawn aided by CT images and then quantitatively expressed as per cent injected dose per gram of tissue (%ID/g). Immunohistochemistry. Immunohistochemistry (IHC) was performed using Dako Autostainer Link 48. The HIF-1α and HIF-2α immunohistochemical procedures and interpretations were standardized based on expression profiles in well-characterized cell lines (786-O, 786-O empty vector, and 786-O VHLreconstituted cell lines) and human ccRCC tissue with known expression for these two proteins by western blot. Multiple commercially available antibodies were evaluated and the antibodies with most consistent results were selected for further studies. Briefly, for HIF-1α and HIF-2α staining, after hydration, antigen retrieval was accomplished with EnVision FLEX Target Retrieval Solution, Low pH (K800521, Dako) in a Dakocytomation Pascal pressure cooker; Ki67 and CD31 antigen retrieval was done using a Dako PT Link. Slides were incubated in 3% hydrogen peroxide for 10 min. Primary antibodies were added and incubated for 40 min at room temperature. Primary antibodies: HIF-1α (1:500, NB100-105, Novus), HIF-2α (1:200, sc-46691, Santa Cruz), Ki67 (ready-to-use, IR-626, Dako) and CD31 (1:200, LS-B1932, LifeSpan BioSciences). After rinsing with wash buffer, EnVision FLEX mouse/rabbit linker (K802121/K800921, Dako) was applied to the tissue and incubated for 10 min. Secondary antibody, EnVision FLEX/HRP (K800021, Dako), was incubated for 20 min. Sections were then processed using the Envision FLEX Substrate Working Solution for 10 min followed by dehydration in a standard ethanol-xylene series and mounting medium (8310-4, Thermo Scientific). IHC of HIF-1α and HIF-2α was performed on pre-treated tumourgraft tissue for n = 22 tumourgraft lines. Appropriate positive and negative controls were used with each run of immunostaining. The percentage of tumour cells in the entire section examined was recorded by a pathologist blinded to the western blot results. Only a 2 or 3+ nuclear positive reaction was considered as positive expression (staining scale: 0 = no staining, 1 = weak, 2 = moderate, 3 = strong). Proliferation index and microvessel quantification. To assess tumour proliferation index, we performed immunostaining for Ki67, and to assess tumour microvessels, we performed CD31 immunostaining on tumours following treatment with vehicle or PT2399. IHC was completed on n = 10 sensitive tumourgraft lines, with n = 28 vehicle-treated tumours and n = 31 PT2399-treated tumours. Slides were digitally scanned using an Aperio Scanscope AT Turbo and reviewed using the Aperio eSlide Manager (ver. 12.0.0.5040) and Imagescope (ver. 12.1.0.5029) systems (Leica Biosystems). For Ki67, Aperio Genie (ver. 11.2) pattern recognition software was used to identify and select tumour areas for quantitative analysis with the Aperio Nuclear algorithm (version 11.2), yielding a percentage of tumour nuclei positive for Ki67. In a small subset of tumours where Genie inadequately identified tumour cells, representative tumour regions were manually selected (tumour necrosis areas were avoided) and reanalysed. Quantitative measurements of microvessels, including density and average lumen area, were obtained using the Aperio Microvessel algorithm (version 11.2) from manually selected representative tumour regions. Real-time PCR. RT-PCR data was generated for 16 tumourgraft trials, except for CA9 and LDHA, which were evaluated in 12 tumourgraft trials. Three RT-PCR reactions were run concurrently for each tumour. Total RNA was isolated as described previously 31 . cDNA was synthesized using iScript Reverse Transcription Supermix for RT-qPCR (170-8841, Bio-Rad). qRT-PCR was performed on a Bio-Rad CFX96 Real-Time PCR system using iTaq Universal SYBR Green SMX (1725124, Bio-Rad). Primers were synthesized by Invitrogen. Primers sequence available upon request. VHL methylation. HIF2-I sensitive ccRCC tumourgrafts that had wild-type VHL status (XP164, XP373, XP453, and XP454) were tested for VHL methylation using the Affymetrix Promoter Methylation PCR Kit (MP1100). Immunoprecipitation and western blot. Tumour tissue was lysed in IP buffer containing 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 5% glycerol, 0.5 mM DTT, with 3-4 freeze-thaw cycles. 10-20% of the lysate was saved for input; 40 μ g was mixed with 3× loading buffer (10% SDS, 33.3% glycerol, 300 mM DDT, 0.2% bromophenol blue) for input. After pre-clearing the lysate with 50 μ l of a 1:1 solution of recombinant protein G-sepharose 4B (101242, Life Technologies) for 1 h, 1 mg protein was mixed with 20 μ l ARNT/HIF-1β antibody (sc-55526, Santa Cruz) and rocked overnight at 4 °C. 30 μ l protein G-sepharose 4B equilibrated with IP buffer was then added, rocked for 1 h at 4 °C, and spun at 3,000 rpm for 10 s. The supernatant was removed and the beads washed three times with IP buffer containing DTT. 20 μ l of 1× loading buffer was added to the beads and vortexed gently, then boiled for 5 min and spun at max speed for 5 min. The entire sample was loaded for western blot analysis. For western blot analysis, both HIF-1α antibody (A300-286A, Bethyl) and HIF-2α antibody (NB100-122, Novus) were diluted at 1:1,000 in 5% BSA in TBS and incubated overnight at 4 °C. Tubulin antibody (T5168, Sigma) was diluted at 1:5,000. Primary antibodies were detected using horseradish peroxidase-conjugated secondary antibodies (31430, 31460, Pierce) followed by exposure to enhanced chemiluminescence substrate (mixing 1:1 solution 1 (2.5 mM luminol, 0.4 mM pCoumaric acid, 0.1 M Tris-HCl) and solution 2 (0.015% H 2 O 2 , 0.1 M Tris-HCl)). Sanger sequencing. Primer sequences are available upon request.
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Transfections. HEK293T cells (ATCC; no perceived need for authentication; negative for mycoplasma) were cotransfected with the indicated expression plasmids using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. After 36 h, cells were treated with PT2399 (10 μ M) at 37 °C for 5 h, harvested for immunoprecipitation with anti-FLAG beads (A2220-1ML, Sigma) and then subjected to western blot analysis. Plasmid laboratory database: #930 (pcDNA3.1 Flag-HIF1β ), #931 (pcDNA3.1 Flag-HIF1β [F446L]), #932 (pLVX HA-HIF-2α -IRES-zsGreen), and #933 (pLVX-HA-HIF-2α [G323E]-IRES-zsGreen). In silico structural analysis. The G323E and F446L mutations were evaluated using PyMOL and Protein Data Bank 4ZP4 (ref. 28) . ELISA. Mouse VEGF (MMV00), human VEGF (DVE00), and mouse erythropoietin (MEP00B) ELISA kits were from R&D Systems. Briefly, 50 μ l assay diluent was added to each well. 50 μ l of either standard, control, or sample was then added to a well. For mEPO and mVEGF ELISA, the serum was diluted twofold and fivefold, respectively, with calibrator diluent. For hVEGF, no dilution was performed. Plates were incubated for 2 h at room temperature on a horizontal orbital microplate shaker, then aspirated and washed for a total of five washes. After the last wash, 100 μ l of mEPO/mVEGF/hVEGF conjugate was added to each well and incubated for 2 h at room temperature on a shaker. Plates were washed five times with wash buffer and 100 μ l of substrate solution was added to each well and incubated for 30 min at room temperature, during which time the plates were covered to protect from the light. Stop solution was then added to each well, with gentle tapping to ensure thorough mixing. The optical density of each well was determined using a microplate reader set to 450 nm. Wavelength correction was set to 540 nm. The final optical density (OD) value was obtained by subtracting readings at 540 nm from the readings at 450 nm. ELISA data were generated for a total of 20 tumourgraft trials. Proximity ligation assay. Mouse anti-HIF-1α (NB100-105, Novus), mouse anti-HIF-2α (sc-46691X, Santa Cruz) and rabbit anti-ARNT/HIF-1β (A302-765A, Bethyl) were used. Primary antibodies were concentrated and buffers were exchanged using a Vivaspin 500 Centrifugal Concentrator (VS0131, Fisher Scientific). Antibodies were diluted to 1 mg ml −1 in PBS. Primary antibody conjugation was done with a Duolink In situ Probemaker MINUS/PLUS kit (DUO92010 & DUO92009, Sigma-Aldrich). Briefly, 2 μ l of conjugation buffer was added to 20 μ l of the antibody (1 mg ml −1 ), mixed gently, transferred to one vial of lyophilized oligonucleotide (PLUS or MINUS), and incubated at room temperature overnight. 2 μ l of stop reagent was then added to the reaction and incubated at room temperature for 30 min. 24 μ l of storage solution was added and the conjugation stored at 4 °C. Tumour tissue was blocked with PBS-T (0.1% Triton X-100) + 1% BSA for 30 min after antigen retrieval. Conjugated HIF1-α -MINUS, HIF2-α -MINUS and ARNT-PLUS were diluted in blocking buffer containing 1× assay reagent (20× ) at a dilution of 1:50, 1:50, and 1:200, respectively. The mixture was allowed to sit for 20 min at room temperature before diluted primary antibody was added to each sample. Slides were incubated in a humidity chamber overnight at 4 °C. Duolink In situ Detection Reagents Red (DUO92008, Sigma-Aldrich) were used for signal detection. Briefly, slides were washed with wash buffer A, ligation solution containing ligase at a 1:40 dilution was added, and slides were incubated in a preheated humidity chamber for 30 min at 37 °C. After washing in 1× wash buffer A with gentle agitation, amplification solution containing polymerase was added at a 1:80 dilution, and slides were then incubated in a pre-heated humidity chamber for 100 min at 37 °C. After washing in 1× wash buffer B and then 0.01× wash buffer B, slides were dried at room temperature in the dark and mounted with a cover slip using a minimal volume of Duolink In situ Mounting Medium with DAPI (DUO82040, Sigma-Aldrich). After approximately 15 min, slides were analysed by fluorescence microscopy (Olympus) using a 40× objective. Image analysis was done with the ImageJ 1.48V program. Pictures of three fields for each sample were used. At least 100 cells of each sample were counted. RNA sequencing. 23 vehicle-and 23 PT2399-treated tumour RNA samples, including 5 sensitive XPs (XP144, XP164, XP373, XP374, and XP453) and 4 resistant XPs (XP169, XP296, XP490, and XP506), underwent RNA sequencing at the New York Genome Center. RNA sequencing libraries were prepared using the Illumina TruSeq Stranded mRNA Sample Preparation Kit. Briefly, 500 ng total RNA was purified by oligo-dT beads selecting for polyadenylated RNA species and fragmented by divalent cations under elevated temperature. The fragmented RNA underwent first strand synthesis using reverse transcriptase and random primers. Second strand synthesis created the cDNA fragments using DNA polymerase I. Following RNaseH treatment, the cDNA fragments went through end repair, adenylation of the 3′ ends, and ligation of adapters. The cDNA library was enriched using eight cycles of PCR and purified. Quality control consisted of assaying the final library size using the Agilent Bioanalyzer and quantifying the final library by RT-PCR and PicoGreen (fluorescence) methods. A single peak between 250 and 350 bp indicated a properly constructed and amplified library ready for sequencing. Sequencing was performed on a HiSeq 2500 using v4 SBS chemistry according to the Illumina protocol, as described 32 . Sequencing libraries were loaded onto the HiSeq 2500 flowcell for clustering on the cBot using the instrument-specific clustering protocol. Given HiSeq 2500 capabilities (200-250M passed filter 2 × 50-bp sequencing reads per flow cell lane), we sequenced 5 samples per lane in order to obtain a minimum of 50M PF reads per sample. With one exception, > 100 million reads were obtained per sample (median 146,644,355; 95% distribution-free CI: 142,380,928-151,324,826; Extended Data Table 1 ). Any gene with more than 50 reads in any sample was kept; only genes that had low reads in all of the samples were removed. This left 20,667 genes after removal of pseudogenes. cDNA sequences were aligned to a combined index of mouse and human reference sequences with STAR v 2.4.0c. Mouse reads were filtered out and the remaining reads were re-mapped to the NCBI hg37 using STAR aligner (v2.3.1z) 33 . Quantification of genes annotated in Gencode v19 was performed using HTSeq 
